Conflict of Interest Disclosures: Drs Janik, Qiu, Popova, Drevets, Canuso, and Fu and Ms Lane are employees of Johnson & Johnson, and all are stockholders of Johnson & Johnson. Drs Janik, Popova, Drevets, Canuso, and Fu report holding a patent for esketamine for treatment of depression, the rights of which were assigned to Johnson & Johnson. Dr Macaluso reported receiving grant support for research from Alto, Autobahn, Boehringer Ingelheim, Janssen, LivaNova, Merck, Neurocrine, the US National Institutes of Health (NIH)/National Institute of Mental Health (NIMH), Otsuka, the Patient-Centered Outcomes Research Institute (PCORI), and Supernus/Navitor (all clinical trial payments made to the University of Alabama at Birmingham); providing consultancy to edYOU, EmbodyXR, Intra-Cellular Therapies Inc, LivaNova, NuSachi Labs, PharmaTher, Residents Medical, Tactical Mind Solutions, and the University of Missouri; receiving personal fees from Alfa Sigma, edYOU, and LivaNova; receiving nonfinancial support from electroCore for an investigator-initiated trial; holding a patent for intravenous ketamine for amyotrophic lateral sclerosis (held under his and other faculty members’ names by University of Kansas School of Medicine); serving on Janssen’s speakers bureau for esketamine from April 2019 to June 2020; and receiving royalties from Springer Nature and the American Psychiatric Association Publishing (for textbooks published). Dr Mattingly reported receiving grant support for research from AbbVie, Acadia, Akilli, Alkermes, Alto Therapeutics, Autobahn, Avanir, Axsome, Boehringer Ingelheim, Cingulate, Click Therapeutics, Compass, Corium, Emalex, Idorsia, Intra-Cellular Therapies Inc, Johnson & Johnson Innovative Medicine, Karuna, Lumos Labs, Medgenics, Neumora, Neurocrine, NLS Pharma, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, and Teva; providing consultancy to AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Aytu, Biogen, Boehringer Ingelheim, Cerevel, Corium, Eisai, Ironshore, Intra-Cellular Therapies Inc, Janssen, LivaNova, Lumos Labs, Lundbeck, Manus, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sky Therapeutics, Sunovion, Supernus, Takeda, Teva, and Tris Pharma; and serving on the speakers bureau for AbbVie, Alkermes, Angelini, Axsome, Corium, Intra-Cellular Therapies Inc, Ironshore, Janssen, Lundbeck, Luye, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, and Tris Pharma. Dr Shelton reported receiving grant support for research from AbbVie, Alto Pharmaceuticals, Boehringer Ingelheim, Denovo Biopharma, Gate Neuroscience, INmune Bio, Intra-Cellular Therapies Inc, Johnson & Johnson Innovative Medicine, LivaNova PLC, NIMH, Navitor Pharmaceuticals, Neumora, Neurocrine Biosciences, NeuroRx, the NIH, Novartis AG, NRx Pharmaceuticals, Otsuka Pharmaceuticals, PCORI, Sumitomo Pharma America, and Supernus Pharmaceuticals; providing consultancy to Boehringer Ingelheim, Denovo Biopharma, EQUULUS Therapeutics, Evecxia Therapeutics, Johnson & Johnson Innovative Medicine, NeuroRx, Novartis AG, Otsuka Pharmaceuticals, Seelos Therapeutics, Sumitomo Pharma America, and Supernus Pharmaceuticals; and receiving royalties from Springer Nature Group and Wolters-Kluwer NV. Dr Zajecka reported receiving grant support for research from Abbott, Axsome, Boehringer Ingelheim, the Cheryl T. Herman Foundation, COMPASS Pathfinder Limited, Cybin IRL Limited, ElMindA, Hoffman-LaRoche, Johnson & Johnson/Janssen, LivaNova, Neurocrine, Novartis, Otsuka, Praxis, SAGE Therapeutics, and Takeda and providing consultancy to/advisory board participation for Alpha Sigma, ElMindA, Johnson & Johnson/Janssen, and Paragon. No other disclosures were reported.
PubMed
